Stockhouse.com uses cookies on this site. By continuing to use our service, you agree to our use of cookies. Cookies are used to offer you a better browsing experience and to analyze our traffic. We also use them to share usage information with our partners. See full details.
I Agree
×
Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Privacy Policy | Disclaimer

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Privacy Policy | Disclaimer
Please Try Again {{ error }}

Send my password

Return to Login
SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Breaking & Recent News LadRx Corp LADX

Healthcare Biotechnology
LadRx Corp is a biopharmaceutical research and development company specializing in oncology. The Company focuses on the discovery, research and clinical development of anti-cancer drug candidates that employ technologies that target chemotherapeutic drugs to solid tumors and reduce off-target toxicities. The Company’s linker activated drug release (LADR) technology platform consists of an... see more

Recent & Breaking News (OTCQB:LADX)

CytRx to Present at the 2013 Leerink Swann Global Healthcare Conference

Business Wire February 6, 2013

CytRx Receives Recommendation from Data Safety Monitoring Committee to Complete Global Phase 2b Clinical Trial with Tamibarotene as First-Line Treatment for Non-Small-Cell Lung Cancer

Business Wire January 31, 2013

CytRx Announces Positive Results from Animal Trial with Combination Aldoxorubicin and Doxorubicin Therapy

Business Wire January 28, 2013

The Law Firm of Levi & Korsinsky, LLP Launches an Investigation into Possible Breaches of Fiduciary Duty by the Board of Directors of CytRx Corporation in Connection with Executive Compensation

PR Newswire January 23, 2013

Free Research Reports on ALNY, CYTR, IQNT and UNIS Issued by the Bedford Report

Marketwired January 17, 2013

CytRx Promotes Dr. Daniel Levitt to Executive Vice President

Business Wire January 3, 2013

CytRx to Present at the Biotech Showcase 2013 Conference

Business Wire January 2, 2013